GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (NAS:FLGT) » Definitions » ROC (Joel Greenblatt) %

Fulgent Genetics (Fulgent Genetics) ROC (Joel Greenblatt) % : -125.81% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Fulgent Genetics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Fulgent Genetics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -125.81%.

The historical rank and industry rank for Fulgent Genetics's ROC (Joel Greenblatt) % or its related term are showing as below:

FLGT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -190.32   Med: -20.6   Max: 511.14
Current: -78.88

During the past 10 years, Fulgent Genetics's highest ROC (Joel Greenblatt) % was 511.14%. The lowest was -190.32%. And the median was -20.60%.

FLGT's ROC (Joel Greenblatt) % is ranked worse than
62.98% of 235 companies
in the Medical Diagnostics & Research industry
Industry Median: -15.21 vs FLGT: -78.88

Fulgent Genetics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Fulgent Genetics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Fulgent Genetics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics ROC (Joel Greenblatt) % Chart

Fulgent Genetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.39 406.91 511.14 154.71 -78.33

Fulgent Genetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -132.30 -105.29 -87.21 0.87 -125.81

Competitive Comparison of Fulgent Genetics's ROC (Joel Greenblatt) %

For the Diagnostics & Research subindustry, Fulgent Genetics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fulgent Genetics's ROC (Joel Greenblatt) % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's ROC (Joel Greenblatt) % falls into.



Fulgent Genetics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(49.277 + 4.877 + 22.548) - (36.803 + 21.447 + 0.281)
=18.171

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(51.132 + 5.827 + 20.419) - (42.14 + 25.574 + 0.164)
=9.5

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Fulgent Genetics for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-123.548/( ( (85.265 + max(18.171, 0)) + (83.464 + max(9.5, 0)) )/ 2 )
=-123.548/( ( 103.436 + 92.964 )/ 2 )
=-123.548/98.2
=-125.81 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fulgent Genetics  (NAS:FLGT) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Fulgent Genetics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Fulgent Genetics (Fulgent Genetics) Business Description

Traded in Other Exchanges
Address
4978 Santa Anita Avenue, Temple City, CA, USA, 91780
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Executives
Jian Xie officer: Chief Operating Officer C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVE, EL MONTE CA 91731
Hanlin Gao 10 percent owner, officer: Chief Scientific Officer 4399 SANTA ANITA AVE., EL MONTE CA 91731
Paul Kim officer: CFO and Treasurer 4399 SANTA ANITA AVE, EL MONTE CA 91731
Regina E Groves director 5751 COPLEY DRIVE, SAN DIEGO CA 92111
Leonard E Post director
Michael Nohaile director C/O BIO AI ACCELERATION COMPANY, 20 UNIVERSITY AVENUE, CAMBRIDGE MA 02138
John C Bolger director 4978 SANTA ANITA AVENUE, SUITE 205, TEMPLE CITY CA 91780
Ming Hsieh Trust 10 percent owner 4399 SANTA ANITA AVE., EL MONTE CA 91731
Linda Marsh director 100 N. STONEMAN AVE., ROOM 200, ALHAMBRA CA 91801
Ming Hsieh director, 10 percent owner, officer: President and CEO 4399 SANTA ANITA AVE., EL MONTE CA 91731
Fulgent Genetics, Inc. director 4399 SANTA ANITA AVE, EL MONTE CA 91731
Yun Yen director 1301 OAKLAWN ROAD, ARCADIA CA 91006
James Mulay director 6521 THOROUGHBRED LOOP, ODESSA FL 33556
Xi Long Usa, Inc. 10 percent owner #6 XINRUI RD., SCIENCE CITY, LUOGANG DISTRICT, GUANGZHOU CITY F4 510663

Fulgent Genetics (Fulgent Genetics) Headlines